DOVER, Del., Jan. 29, 2024 /PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced the completion of  a single ascending dose Phase 1 clinical study of lomonitinib and initiation of a multiple ascending dose Phase 1 program.

多佛，Del。，2024年1月29日/PRNewswire/--Eilean Therapeutics LLC，一家生物制药公司，致力于发现和开发一流的小分子抑制剂，以靶向血液和实体恶性肿瘤的逃逸突变，今天宣布完成洛莫替尼单次递增剂量1期临床研究，并启动多剂量递增1期计划。

Lomonitinib is a highly potent and selective pan-FLT3/ IRAK4 inhibitor that targets clinically relevant FLT3 mutations (ITD, TKD) including the gatekeeper mutation as well as putative escape pathways. The initial phase 1 program demonstrated excellent safety of lomonitinib with no reportable adverse events at exposures that resulted in robust target engagement.

洛莫替尼是一种高效且选择性的泛FLT3/IRAK4抑制剂，可靶向临床相关的FLT3突变（ITD，TKD），包括看门人突变以及推定的逃逸途径。最初的第一阶段计划证明了洛莫替尼的良好安全性，在暴露时没有可报告的不良事件，从而导致强大的目标参与。

.

.

'The completion of the single ascending dose study of lomonitinib represents an important milestone for Eilean Therapeutics, as we progress, on plan, with an accelerated development of lomonitinib,' stated Iain Dukes, Chief Executive Officer of Eilean Therapeutics. 'The outstanding safety profile at exposures expected to exert a therapeutic benefit should enable lomonitinib to safely target FLT3 mutated AML and provides opportunities for development in multiple therapeutic settings where IRAK4 plays a significant role.'.

艾琳治疗公司首席执行官伊恩·杜克斯（IainDukes）表示：“洛莫尼尼单次递增剂量研究的完成代表了艾琳治疗学的一个重要里程碑，因为我们正在计划中加速开发洛莫尼尼。”预期会产生治疗益处的暴露的突出安全性应使洛莫尼尼能够安全靶向FLT3突变的AML，并为IRAK4发挥重要作用的多种治疗环境提供发展机会。”。

About LomonitinibLomonitinib is a highly potent and selective inhibitor of FLT3 ITD, TKD and other clinically relevant FLT3 mutations, as well as IRAK4. FLT3 mutations are the most frequently identified mutations in AML. There are two main mechanisms of resistance to FLT3 inhibitors: the FLT3-ITD-F691L mutation deemed the 'gatekeeper' mutation that confers resistance to all currently approved FLT3 inhibitors and the activation of the IRAK4 escape pathway.

关于LomonitinibLomonitinib是FLT3 ITD，TKD和其他临床相关FLT3突变以及IRAK4的高效选择性抑制剂。FLT3突变是AML中最常见的突变。对FLT3抑制剂的抗性有两种主要机制：FLT3-ITD-F691L突变被认为是“看门人”突变，赋予对所有目前批准的FLT3抑制剂的抗性和IRAK4逃逸途径的激活。

Lomonitinib inhibits both resistance mechanisms. .

洛莫替尼抑制两种耐药机制。。

About Eilean TherapeuticsEilean Therapeutics LLC is a biopharmaceutical company co-founded by Orbimed, Torrey Pines Investment and Dr John C. Byrd, focused on the discovery and development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic and solid cancers.

关于Eilean Therapeutics LLC Eilean Therapeutics LLC是一家由Orbimed，Torrey Pines Investment和John C.Byrd博士共同创立的生物制药公司，专注于发现和开发针对血液学和实体癌逃逸突变的一流小分子抑制剂。

The company is utilizing a proprietary hybrid AI platform (Expert Systems, Inc.), leveraging its key partners proprietary data, chem/bio tools, knowledge and expertise to choose highly valuable molecular mechanism of pathology, to rationally design, accelerate discovery and optimize development of best-in-class and first-in-class therapies.

该公司正在利用专有的混合人工智能平台（Expert Systems，Inc.），利用其关键合作伙伴的专有数据，化学/生物工具，知识和专业知识来选择极具价值的病理分子机制，以合理设计，加速发现和优化一流和一流疗法的开发。

Eilean Therapeutics' goal is to utilize its capabilities and platform to become a leader in developing novel breakthrough medicines to maximize the clinical benefit when treating hematologic and solid malignancies. For more information visit www.eileanther.com.

Eilean Therapeutics的目标是利用其能力和平台成为开发新型突破性药物的领导者，以最大限度地提高治疗血液和实体恶性肿瘤的临床效益。有关更多信息，请访问www.eileanther.com。

Media Contact:Amy BurdCSO[email protected]

媒体联系人：Amy BurdCSO[受电子邮件保护]

SOURCE Eilean Therapeutics

来源Eilean Therapeutics